MR1 and neoplasm: A wider panel of flow cytometry-compliant antibodies which can assess lymphocyte subsets present in cancer tissue based on phenotype and physiological status (e.g. exhausted vs. active, cytotoxic potential, type of recognition including MHC class I/II, CD1, MIC1A/B, MR1 restricted T-cells) prior to processing for cell culture would be an immense addition to clinical immunotherapy protocols (Table 1), augmenting findings from immunohistology analysis of tumor tissue.